Rapamycin and FK506 binding proteins (immunophilins)
Heinz Fretz, Stuart L. Schreiber(Broad Institute), Barbara E. Bierer(Brigham and Women's Hospital), Mark W. Albers(Harvard University), Steven J. Burakoff(Pfizer (United States)), Robert F. Standaert(Howard Hughes Medical Institute), William S. Lane(Brigham and Women's Hospital), Andrzej Gałat(Commissariat à l'Énergie Atomique et aux Énergies Alternatives)
Cited by 135